At the meeting, the Deputy PM affirmed that the Government will create the most favorable conditions for MSD's investment and cooperation projects. She called on the group to regard Viet Nam as a stable and reliable strategic partner, move ahead with plans to invest in a pharmaceutical and vaccine manufacturing plant, and accelerate the transfer of HPV vaccine technology to Viet Nam Vaccine Joint Stock Company (VNVC).
Gailhardou said that Viet Nam was among the group's 10 largest markets in the region.
    |
 |
|
Participants in the meeting |
In 2025, MSD supplied medicines and vaccines to more than 400 million people worldwide, including 2.3 million in Viet Nam. He spoke highly of Viet Nam's focus on disease prevention, as reflected in the Law on Disease Prevention and the inclusion of four vaccines, including the HPV vaccine, in the National Expanded Program on Immunization through 2030.
Earlier that morning, MSD and VNVC announced a cooperation plan on technology transfer, manufacturing and localization of strategically important vaccines, contributing to stronger vaccine security and Viet Nam's self-reliance.
Tra acknowledged MSD's contributions over the past 30 years. She noted that the group had introduced around 20 advanced medicines and vaccines to Viet Nam and pioneered the introduction of Keytruda cancer immunotherapy for Vietnamese patients. The drug now has 28 approved indications across 14 tumor types.
MSD has supported around 7,500 cancer patients, providing medicines worth approximately 4 trillion VND (155.41 USD) and covering up to 75% of treatment costs. It has also invested trillions of VND in clinical research and pledged an additional 40 million USD in 2026. The group has further provided HPV vaccines at preferential prices through the United Nations-backed Gavi vaccine alliance mechanism until the end of 2027.
The Deputy PM said Viet Nam was now enjoying an unprecedentedly favorable policy and institutional environment. Politburo Resolution No. 72-NQ/TW dated September 9, 2025, on breakthrough solutions to strengthen public health protection, care and improvement, shifts the focus towards preventive healthcare, with the goal of providing people with basic free medical services within their health insurance coverage by 2030, following an appropriate roadmap.
The Pharmaceutical Industry Development Strategy through 2030 aims to make Viet Nam a high-value pharmaceutical manufacturing hub in ASEAN, with the domestic market projected to reach approximately 10 billion USD in 2026 and grow by an average of 8-10% annually. The HPV vaccine is officially included in the National Expanded Program on Immunization on July 1, 2026.
Regarding the transfer of HPV vaccine technology between MSD and VNVC, the Deputy PM welcomed the cooperation and expressed the Government's expectation that technology transfer would extend beyond manufacturing and packaging to encompass pharmaceutical technologies and next-generation technologies, in full compliance with Vietnamese law.
She called for a review of treatment outcomes and health economic effectiveness to update the list of medicines covered by health insurance, ensuring transparency and maintaining the financial balance of the Health Insurance Fund. The Deputy PM also said the Government would undertake a comprehensive revision of the Law on Pharmacy to establish a more enabling regulatory framework.
The Deputy PM urged MSD to consider investing in a pharmaceutical and vaccine manufacturing plant in Viet Nam.
She also proposed that MSD act as a focal point to help Viet Nam negotiate directly with pharmaceutical groups, reducing intermediaries to ensure reasonable and transparent pricing.
Source: VNA